Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
Copyright © 2022 Danielle Rosa Beserra et al..
COVID-19 has several mechanisms that can lead to lymphocyte depletion/exhaustion. The checkpoint inhibitor molecule programmed death protein 1 (PD-1) and its programmed death-ligand 1 (PDL-1) play an important role in inhibiting cellular activity as well as the depletion of these cells. In this study, we evaluated PD-1 expression in TCD4+, TCD8+, and CD19+ lymphocytes from SARS-CoV-2-infected patients. A decreased frequency of total lymphocytes and an increased PD-1 expression in TCD4+ and CD19+ lymphocytes were verified in severe/critical COVID-19 patients. In addition, we found a decreased frequency of total monocytes with an increased PD-1 expression on CD14+ monocytes in severe/critical patients in association with the time of infection. Moreover, we observed an increase in sPD-L1 circulant levels associated with the severity of the disease. Overall, these data indicate an important role of the PD-1/PDL-1 axis in COVID-19 and may provide a severity-associated biomarker and therapeutic target during SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2022 |
|---|---|
| Enthalten in: |
Journal of immunology research - 2022(2022) vom: 11., Seite 9764002 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beserra, Danielle Rosa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 17.08.2022 Date Revised 23.08.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1155/2022/9764002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344900886 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344900886 | ||
| 003 | DE-627 | ||
| 005 | 20231226023832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2022/9764002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344900886 | ||
| 035 | |a (NLM)35971391 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beserra, Danielle Rosa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2022 | ||
| 500 | |a Date Revised 23.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Danielle Rosa Beserra et al. | ||
| 520 | |a COVID-19 has several mechanisms that can lead to lymphocyte depletion/exhaustion. The checkpoint inhibitor molecule programmed death protein 1 (PD-1) and its programmed death-ligand 1 (PDL-1) play an important role in inhibiting cellular activity as well as the depletion of these cells. In this study, we evaluated PD-1 expression in TCD4+, TCD8+, and CD19+ lymphocytes from SARS-CoV-2-infected patients. A decreased frequency of total lymphocytes and an increased PD-1 expression in TCD4+ and CD19+ lymphocytes were verified in severe/critical COVID-19 patients. In addition, we found a decreased frequency of total monocytes with an increased PD-1 expression on CD14+ monocytes in severe/critical patients in association with the time of infection. Moreover, we observed an increase in sPD-L1 circulant levels associated with the severity of the disease. Overall, these data indicate an important role of the PD-1/PDL-1 axis in COVID-19 and may provide a severity-associated biomarker and therapeutic target during SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Alberca, Ricardo Wesley |e verfasserin |4 aut | |
| 700 | 1 | |a Branco, Anna Claudia Calvielli Castelo |e verfasserin |4 aut | |
| 700 | 1 | |a de Mendonça Oliveira, Luana |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza Andrade, Milena Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Gozzi-Silva, Sarah Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira, Franciane Mouradian Emidio |e verfasserin |4 aut | |
| 700 | 1 | |a Yendo, Tatiana Mina |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva Duarte, Alberto José |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Maria Notomi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology research |d 2014 |g 2022(2022) vom: 11., Seite 9764002 |w (DE-627)NLM237451581 |x 2314-7156 |7 nnns |
| 773 | 1 | 8 | |g volume:2022 |g year:2022 |g day:11 |g pages:9764002 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2022/9764002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2022 |j 2022 |b 11 |h 9764002 | ||